NCT06600178View on ClinicalTrials.gov

Study Targeting Myocardial Perfusion and Symptom Relief in Women with SGLT2 Inhibitors (STRONG)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions
Angina Patients with Non-obstructive Coronary Artery DiseaseCoronary Microvascular DiseaseCoronary Microvascular Dysfunction (CMD)
Interventions
DRUG

Dapagliflozin 10Mg Oral Tablet

Dapagliflozin 10mg oral

DRUG

Placebo

Placebo tablet given to subject vs. active drug.

Trial Locations (1)

22908

UVA Health, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER